Nippon India Mutual Fund has disclosed the acquisition of additional shares in syngene international through open market purchases, increasing its total shareholding in the biotechnology services company to 7.12%. The disclosure was made under SEBI regulations governing substantial acquisition of shares.

Share Acquisition Details

The mutual fund acquired 16,00,307 shares of Syngene International between February 16, 2026, and April 10, 2026, through open market transactions. This acquisition represents 0.3972% of the company's total voting share capital.

Company Share Capital Structure

Syngene International's equity share capital remained unchanged following the transaction. The company maintains a total equity share capital of ₹4,02,93,94,200, comprising 40,29,39,420 shares with a face value of ₹10 per share.

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Nippon India Mutual Fund, operating through Nippon Life India Trustee Limited, confirmed that it does not belong to the promoter or promoter group of Syngene International.

The mutual fund's shares in Syngene International are listed on both the National Stock Exchange of India Limited and BSE Limited. The acquisition was completed without any encumbrances, voting rights other than equity shares, or convertible securities.

Fund Details

Nippon India Mutual Fund operates from its registered office at 30th Floor, One Lodha Place, Senapati Bapat Marg, Lower Parel, Mumbai. The fund manages investments on behalf of its unit holders through various equity and debt schemes across different market segments.

Syngene International has witnessed a significant institutional investment as DSP Trustee Private Limited crossed the 5% shareholding threshold through a substantial share acquisition. The transaction, completed on April 07, 2026, involved the purchase of 9,93,389 shares through open market operations, prompting mandatory regulatory disclosures under SEBI takeover regulations.

Acquisition Details and Shareholding Changes

The share acquisition was executed by multiple schemes under DSP Mutual Fund, managed by DSP Asset Managers Private Limited. The participating schemes included DSP Large Cap Fund, DSP Equity Savings Fund, DSP Aggressive Hybrid Fund, DSP Nifty 500 Index Fund, DSP Nifty Healthcare Index Fund, DSP Nifty Smallcap 250 Index Fund, and DSP Nifty Midcap 150 Quality 50 Index Fund.

Regulatory Framework and Compliance

DSP Trustee Private Limited acts as the trustee for schemes launched by DSP Mutual Fund and DSP Alternative Investment Fund, with DSP Asset Managers Private Limited serving as the Investment Manager. The entity also manages DSP Global Funds ICAV, with all these entities collectively falling within the definition of persons acting in concert under SEBI regulations.

The acquisition triggered reporting requirements under Section 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the combined shareholding exceeded the 5% threshold. The formal disclosure was filed on April 09, 2026, by Dr. Pritesh Majmudar, Compliance Officer and Company Secretary at DSP Asset Managers Private Limited.

Transaction Structure and Market Impact

The shares were acquired through ordinary equity transactions in the open market, with no involvement of preferential allotment, rights issues, or other special arrangements. The acquisition represents a 0.24% increase in shareholding, bringing the total stake to 5.03% of Syngene International's paid-up capital of Rs. 4,02,93,94,200.

The acquisition demonstrates continued institutional interest in Syngene International, with DSP's various fund schemes collectively building a significant position in the biotechnology company. The transaction was executed across multiple fund categories, including large-cap, hybrid, and specialized index funds, indicating diversified investment strategy across DSP's portfolio management approach.